SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine
Phase 2
Completed
- Conditions
- InfluenzaOrthomyxoviridae Infections
- Interventions
- Biological: Inactivated influenza vaccine (split virion) NH 2007-2008 formulation
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2014-01-17
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 130
- Registration Number
- NCT00491257
Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose
Phase 3
Completed
- Conditions
- Hepatitis A
- Interventions
- Biological: Hepatitis A vaccine (HAVRIX 720)Biological: Hepatitis A vaccine AVAXIM 80U
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 720
- Registration Number
- NCT00483470
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
Phase 3
Completed
- Conditions
- VaricellaMeningococcal MeningitisMumpsMeaslesRubella
- Interventions
- Biological: Measles-mumps-rubella-varicella vaccineBiological: Routine paediatric vaccine - Pneumococcal conjugate (PCV)Biological: Routine paediatric vaccine - Hepatitis A
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1378
- Registration Number
- NCT00483574
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age
Phase 3
Completed
- Conditions
- TetanusDiphtheriaPertussis
- Interventions
- Biological: Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)Biological: DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)
- First Posted Date
- 2007-04-30
- Last Posted Date
- 2014-02-07
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1045
- Registration Number
- NCT00467519
Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 590
- Registration Number
- NCT00466245
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
Phase 1
Completed
- Conditions
- Pandemic InfluenzaInfluenza A Virus InfectionOrthomyxoviridae Infections
- Interventions
- Biological: A/H5N1 inactivated, split-virion influenza vaccine+AdjuvantBiological: A/H5N1 inactivated, split-virion influenza vaccine
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 251
- Registration Number
- NCT00457509
REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children
Phase 3
Completed
- Conditions
- DiphtheriaPoliomyelitisTetanus
- Interventions
- Biological: REVAXIS®Biological: DT-Polio®
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 760
- Registration Number
- NCT00447525
Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia
Phase 3
Completed
- Conditions
- Neisseria MeningitidisMeningococcal Infections
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 450
- Registration Number
- NCT00444951
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
Phase 2
Completed
- Conditions
- West Nile Fever
- Interventions
- Biological: ChimeriVax-WN02 High DoseBiological: ChimeriVax-WN02 Medium DoseBiological: ChimeriVax-WN02 Low DoseBiological: 0.9% Saline solutionBiological: 0.9 % NaCl solution
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 208
- Registration Number
- NCT00442169
- Locations
- 🇺🇸
Idaho Infectious Diseases, PLLC, Idaho Falls, Idaho, United States
🇺🇸PRA International Clinical Pharmacology Center, Lenexa, Kansas, United States
🇺🇸Bio-Kinetic Clinical Applications, Inc., Springfield, Missouri, United States
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
Phase 3
Completed
- Conditions
- RubellaMeningococcal MeningitisMumpsMeaslesVaricella
- Interventions
- Biological: Measles, Mumps, Rubella and VaricellaBiological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1664
- Registration Number
- NCT00422292
© Copyright 2025. All Rights Reserved by MedPath